TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02045901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclegis
Description: On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Study: NCT02495662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-liposomal prednisolone sodium phosphate
Description: Liposomal prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline
Study: NCT03348163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/FTC/TAF
Description: B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current ART
Description: Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
Study: NCT03203122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPL laser
Description: IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No sham treatment
Description: The treatment is slightly painful, and noisy. Sham treatment impossible
Study: NCT02770378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
Study: NCT02560012

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: 400 mg (2 tablets) orally twice daily without food

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: 10 mg orally once daily with or without food

Intervention type: DRUG
Group type: OTHER
Intervention: Axitinib
Description: 5 mg orally twice daily
Study: NCT01921842

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NAP-SACC Child Care Wellness Program
Description: Nutrition And Physical activity Self-Assessment for Child Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAP-SACC Child Care Wellness Program
Description: Nutrition And Physical activity Self-Assessment for Child Care
Study: NCT01798433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One stent technique alone
Description: One stent technique alone with drug-eluting stent
Study: NCT04086342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a vehicle oil that will match CHI-902.
Study: NCT00255749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study: NCT01798433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One stent technique + Elective FKB
Description: One stent technique + Elective FKB with drug-eluting stents + balloon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Provisional approach
Description: Provisional approach with drung-eluting stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elective 2-stent
Description: Elective 2-stent with drug-eluting stents
Study: NCT04033328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily in each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: ORIC-101 once daily in each 28-day cycle
Study: NCT03111329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No aspiration of gastric residuals
Description: No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
Study: NCT04420663

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pleural Manometry
Description: Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
Study: NCT01998308

Intervention type: DRUG
Intervention: Crespine gel
Description: 50 Knees will have single injection of Crespine gel

Intervention type: DRUG
Intervention: Intragel
Description: 50 Knees will have single injection of 2 ampules of Intragel
Study: NCT02770378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril
Description: Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
Study: NCT04033328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide 40 MG oral capsule [Xtandi]
Description: 160 mg once daily in each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide 40 MG oral capsule [Xtandi]
Description: 160 mg once daily in each 28-day cycle
Study: NCT02159495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT02770378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
Study: NCT01937078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
Study: NCT01777022

Intervention type: OTHER
Group type: OTHER
Intervention: A package of interventions
Description: A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth
Study: NCT01240629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT01998308

Intervention type: DRUG
Intervention: Crespine plus gel
Description: 50 Knees will have single injection of Crespine Plus Gel
Study: NCT01240629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin-GnRH agonist conjugate AEZS-108
Description: Given IV
Study: NCT00617942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 neo-adjuvant
Description: Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 neo-adjuvant
Description: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 adjuvant
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 adjuvant
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Study: NCT03521089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001
Description: Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001
Description: Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
Study: NCT03642002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toning
Description: Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable

Intervention type: OTHER
Group type: OTHER
Intervention: Ocean drum & SOK melody
Description: Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOK
Description: Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process
Description: Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holding Harmonic Container
Description: Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment
Study: NCT04892095

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational cross-sectional study. No intervention is considered.
Study: NCT04235673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: orally administered drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administered drops
Study: NCT04115904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ibuprofen for post operative pain
Description: All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
Study: NCT01998308

Intervention type: DRUG
Intervention: Monovisc
Description: 50 Knees will have single injection of Monovisc
Study: NCT03368846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: \[14C\]-Varlitinib
Study: NCT02834351

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle Biopsy
Description: A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy
Description: A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups.
Study: NCT00387621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Study: NCT03969446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study: NCT02609789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
Study: NCT03969446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02609789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
Study: NCT03969446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00255749

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: epoetin alfa
Study: NCT01517282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MOR103
Description: Anti-GM-CSF monoclonal antibody
Study: NCT00958282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine/Behavior Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00707616

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: one time 75g oral glucose tolerance test for measurement of insulin secretion and action
Study: NCT03583476

Intervention type: DRUG
Intervention: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.

Intervention type: DRUG
Intervention: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.

Intervention type: DRUG
Intervention: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.

Intervention type: DRUG
Intervention: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
Study: NCT03817827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: this group will receive Acupuncture for 30 minutes three times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: this group will receive Acupuncture for 30 minutes three times per week
Study: NCT03860870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol Oral Product
Description: Subjects ingest 4x20 microgram clenbuterol tablets
Study: NCT03817827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet supplementary
Description: Diet supplementary with soy product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet supplementary
Description: Diet supplementary with soy product
Study: NCT05639582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fractal analysis
Description: fractal analysis is a method that numerically expresses bone changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fractal analysis
Description: fractal analysis is a method that numerically expresses bone changes.
Study: NCT03860870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects ingest placebo tablets
Study: NCT01494753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2345
Description: One drop at 8.00pm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin
Description: One drop at 8.00pm.
Study: NCT01347515

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day.
Study: NCT01845688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Tablets & QingReMoShen Granule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan Tablets & Placebo Granule
Study: NCT01531088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active medication monitoring
Description: Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
Study: NCT00712790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Tablet, 400mg orally, twice daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: one time treatment and capped at 3.0 Gbq
Study: NCT03396003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GALILEI G6 Lens Professional
Description: Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Pentacam AXL
Description: A single measurement of the eye will be taken using the Oculus Pentacam AXL